Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | DGKA | P23743 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetyl Palmitate SCHEMBL28216712 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL14562870 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL7523298 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL27302948 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL7895803 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL27567967 | 1.00 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL27600324 | 0.97 | KDM4E (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL8378713 | 0.93 | KDM4E (0.69) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Glycerin SCHEMBL28228192 | 0.93 | LMNA (0.73) | KDM4EDUSP3MEN1KMT2ALMNA | |
| Cetyl Palmitate SCHEMBL6241713 | 0.92 | KDM4E (0.88) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084821-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | MICRODERMIS CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8536228-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120022165-A1 | TRANSDERMAL COMPOSITIONS | MICRODERMIS CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-8101163-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-7893285-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7888393-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100203005-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20040122105-A1 | Transdermal compositions | DRSS GLOBAL, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026259-A2 | TRANSDERMAL COMPOSITIONS | BETTLE GRISCOM III (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | KDM4E 4067/4885DUSP3 1289/4885MEN1 2596/4885 |
| US-20100203005-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | KDM4E 4067/4885DUSP3 1289/4885MEN1 2596/4885 |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, DGKG | KDM4E 4108/4885DUSP3 1386/4885MEN1 2399/4885 |
| US-20120022165-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | KDM4E 4067/4885DUSP3 1289/4885MEN1 2596/4885 |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | KDM4E 4067/4885DUSP3 1289/4885MEN1 2596/4885 |
| US-20040122105-A1 | Transdermal compositions | S100A10, DGKG, COX6C | KDM4E 3526/4885DUSP3 1479/4885MEN1 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.